Decisions of the Unified Patent Court recorded under "Life sciences and pharma" in UPC Litigation Watch, the case law database maintained by Dhenne Avocats.
Decisions of the Unified Patent Court in pharmaceuticals, biotechnology and medical devices: validity and sufficiency, SPCs, generic and biosimilar launches, provisional measures and evidence.
121 decisions recorded
In a decision of 24 March 2026 (UPC_CoA_641/2025), the UPC Court of Appeal allowed Sanofi Biotechnology SAS and Regeneron Pharmaceuticals Inc. to withdraw their appeal against the Düsseldorf Local Division decision of 13 May 2025 (UPC_CFI_505/2023, EP 3 536 712), which dismissed…
In a decision of 24 March 2026 (UPC_CoA_646/2025), the UPC Court of Appeal allowed Amgen N.V. and six other Amgen companies to withdraw their appeal against the Düsseldorf Local Division decision of 13 May 2025 (UPC_CFI_505/2023, EP 3 536 712), insofar as…
In an order of 18 March 2026 (UPC_CoA_930/2025), the UPC Court of Appeal dismissed EOFlow Co., Ltd.'s appeal against the Milan Central Division order of 4 December 2025 (UPC_CFI_1167/2025), which had refused to treat as confidential under Rule 262.2 business information disclosed…
By order of 26 February 2026 (UPC_CoA_34/2026), the standing judge of the Court of Appeal dismissed as inadmissible EOFlow's request for discretionary review and its auxiliary request for leave to appeal.
In an order of 19 February 2026 (UPC_CFI_283/2026), the Paris Local Division partly granted the law firm Gowling WLG access to the file of the provisional measures proceedings between Merz and Viatris Santé (UPC_CFI_697/2025), concerning EP 2 377 536 and supplementary protection…
By order of 18 February 2026 in the joined proceedings UPC_CoA_528/2024 and UPC_CoA_529/2024 (EP 3 666 797), the Court of Appeal rejected Sanofi and Regeneron's request for suspensive effect of their application for rehearing of the decision of 25 November 2025, which…
By order of 18 February 2026 in proceedings UPC_CFI_616/2025 and UPC_CFI_1439/2025 (EP 2 590 626), the judge-rapporteur of the Hague Local Division allowed GSK to extend its action against Moderna to the mNEXSPIKE product, dismissed Moderna's application to strike material from the…
The Court of Appeal holds inadmissible the appeal by EOFlow Co., Ltd. against the order of the Milan Central Division of 4 December 2025 (UPC_CFI_1167/2025), which, at the request of Insulet Corporation, had imposed penalty payments of EUR 150,000 for non-compliance with…
In the appeal brought by Merz Pharmaceuticals LLC, Merz Therapeutics GmbH and Merz Pharma France against the order of the Paris Local Division of 21 November 2025 (UPC_CFI_697/2025), which had refused their application for provisional measures against Viatris Santé based on French…
The judge-rapporteur of the Court of Appeal, sitting alone, grants Herbert Smith Freehills Kramer LLP access to Insulet Corporation’s Statement of Appeal and to a redacted version of EOFLow Co., Ltd.’s Statement of Response in appeal UPC_CoA_768/2024 (EP 4 201 327), decided…
The Court of Appeal disposes, under Rule 360 RoP, of the procedural appeal brought by Viatris Santé against the order of the Paris Local Division of 29 October 2025 (UPC_CFI_697/2025), which had disregarded late-filed exhibits in provisional measures proceedings brought by Merz…
The Munich Local Division revokes Sanofi’s European patent EP 2 493 466 in its entirety. The patent covers cabazitaxel in combination with prednisone or prednisolone for treating metastatic castration-resistant prostate cancer previously treated with a docetaxel-based regimen.
The Milan Central Division ordered EOFLOW to pay a penalty of EUR 150,000 for violating the preliminary injunction granted by the Court of Appeal on 30 April 2025, on the basis of evidence that EOFLOW had exported 11,520 insulin pump devices to…
In the infringement action brought by GlaxoSmithKline Biologicals SA against fifteen Moderna group companies (UPC_CFI_619/2025), The Hague Local Division orders of its own motion, under Rule 302.1 RoP, that the single counterclaim for revocation directed at EP 4 066 856 and EP…
By decision of 27 November 2025, the Milan Central Division, hearing Pari Pharma’s revocation action against Koninklijke Philips’ EP 3 397 329 B1 (air-flow in a nebulizer head), holds claim 1 as granted to lack novelty but maintains the patent as amended…